Model-Guided Antipsychotic Dose Reduction in Schizophrenia: A Pilot, Single-Blind Randomized Controlled Trial

Area of Science:

• Psychiatry
• Pharmacology
• Clinical Trials

Background:

• Antipsychotic dose reduction in schizophrenia is often avoided due to relapse fears.
• Developing personalized dosing strategies is crucial for managing schizophrenia.
• Targeting dopamine D2 receptor occupancy is a key factor in antipsychotic efficacy.

Purpose of the Study:

• To develop and evaluate a model for calculating individualized oral antipsychotic doses.
• To determine the feasibility of dose reduction based on target dopamine D2 receptor occupancy.
• To compare a model-guided dose reduction strategy with standard dose maintenance in schizophrenia patients.

Main Methods:

• A 52-week, single-blind, randomized controlled trial involving 35 stable schizophrenia patients.
• Patients were assigned to either a dose reduction group (n=17) or a dose maintenance group (n=18).
• Dose reduction was guided by models calculating doses for 65% D2 receptor occupancy using plasma concentrations.

Main Results:

• Doses of risperidone and olanzapine were significantly reduced in the dose reduction group.
• Completion rates were similar between groups (70.5% vs 72.2%).
• No significant differences in overall symptom scores (Positive and Negative Syndrome Scale), but a significant difference in positive subscale scores on the Clinical Global Impression-Schizophrenia scale was observed.

Conclusions:

• Model-guided antipsychotic dose reduction is comparable to dose maintenance regarding dropout rates.
• The strategy shows potential for managing schizophrenia treatment.
• Further investigation into safety aspects of this dose reduction method is warranted.